Femasys is trading at $1.74, up 5.45% after-hours; no confirmed company-specific announcement explains the rise.

  • This compares with the October 16 regular-session close of $1.65.
  • The latest company update found was October 14, when FemBloc trial enrollment sites doubled to twelve; no October 16 company-specific announcement was confirmed.
  • Major U.S. indexes finished lower, but available evidence does not establish broad-market direction as the reason for the move. No after-hours volume data was provided.